Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 3
2019 2
2020 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Practical Considerations in Managing Relapsed Multiple Myeloma.
Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ. Agarwal A, et al. Among authors: friend r. Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):69-77. doi: 10.1016/j.clml.2016.11.010. Epub 2016 Nov 23. Clin Lymphoma Myeloma Leuk. 2017. PMID: 27986429 Review.
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Bhutani M, Foureau DM, Robinson M, Guo F, Fesenkova K, Atrash S, Paul B, Varga C, Friend R, Pineda-Roman M, Rigby K, Symanowski JT, Norek S, Tucker MR, Druhan LJ, Voorhees PM, Usmani SZ. Bhutani M, et al. Among authors: friend r. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):535-544.e1. doi: 10.1016/j.clml.2023.03.016. Epub 2023 Apr 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37127471 Clinical Trial.
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.
Hamadeh IS, Reese ES, Arnall JR, Kachur E, Martin AL, Schneider M, Friend R, Paul B, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Hamadeh IS, et al. Among authors: friend r. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):526-532.e1. doi: 10.1016/j.clml.2020.02.014. Epub 2020 Mar 7. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32279951
Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Hussain MJ, Robinson MM, Hamadeh I, Arnall J, Bhutani M, Atrash S, Friend R, Pineda-Roman M, Symanowski JT, Usmani SZ, Voorhees PM. Hussain MJ, et al. Among authors: friend r. Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11. Br J Haematol. 2019. PMID: 30536372 Free article. No abstract available.
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, Usmani SZ. Bhutani M, et al. Among authors: friend r. Biol Blood Marrow Transplant. 2019 Mar;25(3):459-465. doi: 10.1016/j.bbmt.2018.11.015. Epub 2018 Nov 24. Biol Blood Marrow Transplant. 2019. PMID: 30481597 Free article.
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ. Bhutani M, et al. Among authors: friend r. Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6. Lancet Haematol. 2017. PMID: 28863804